| (Rac)-Neurodegenerative Disorder-Targeting Compound 1 |
|
|
|
|
|
|
|
|
| (Rac)-Z-FA-FMK |
|
|
|
|
|
|
|
|
| (S,S)-Z-FA-FMK |
|
|
|
|
|
|
|
|
| 2-Cyanopyrimidine |
|
|
|
|
|
|
|
99.92% |
| 3-Epiursolic Acid |
|
|
|
|
|
|
|
99.77% |
| 4-Methylesculetin |
|
|
|
|
|
|
|
99.27% |
| 6-Hydroxytetrangulol |
|
|
|
|
|
|
|
|
| ABP 25 |
|
|
|
|
|
|
|
|
| Abz-FRF(4NO2) |
|
|
|
|
|
|
|
|
| Abz-GIVRAK(Dnp) |
|
|
|
|
|
|
|
|
| Ac-FR-AFC TFA |
|
|
|
|
|
|
|
99.51% |
| Ac-Glu-Asp(EDANS)-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Gly-Lys(DABCYL)-Glu-NH2 |
|
|
|
|
|
|
|
|
| Ac-Glu-Asp(EDANS)-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Gly-Lys(DABCYL)-Glu-NH2 acetate |
|
|
|
|
|
|
|
99.44% |
| Ac-Leu-Val-Lys-Aldehyde |
|
|
|
|
|
|
|
|
| Ac-PLVE-FMK |
|
|
|
|
|
|
|
98.0% |
| Ac-RR-AFC TFA |
|
|
|
|
|
|
|
99.56% |
| Ac-VLPE-FMK |
|
|
|
|
|
|
|
99.0% |
| AEP-IN-1 |
|
|
|
|
|
|
|
|
| AEP-IN-2 |
|
|
|
|
|
|
|
99.13% |
| AEP-IN-3 |
|
|
|
|
|
|
|
99.95% |
| ALLM |
|
|
|
|
|
|
|
98.60% |
| AM4299B |
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 113 |
|
|
|
|
|
|
|
|
| anti-NSCLC agent-2 |
|
|
|
|
|
|
|
|
| Anti-osteoporosis agent-9 |
|
|
|
|
|
|
|
|
| Arg-Arg-AMC |
|
|
|
|
|
|
|
|
| Arg-Arg-AMC acetate |
|
|
|
|
|
|
|
99.55% |
| ASPER-29 |
|
|
|
|
|
|
|
|
| Asperphenamate |
|
|
|
|
|
|
|
98.0% |
| Atg4B-IN-2 |
|
|
|
|
|
|
|
98.03% |
| Aurantiamide acetate |
|
|
|
|
|
|
|
99.85% |
| BI-1124 |
|
|
|
|
|
|
|
|
| BI-1915 |
|
|
|
|
|
|
|
|
| BI-9740 |
|
|
|
|
|
|
|
|
| BJ-2302 |
|
|
|
|
|
|
|
|
| BML-244 |
|
|
|
|
|
|
|
|
| Bz-FVR-AMC |
|
|
|
|
|
|
|
99.83% |
| Bz-FVR-AMC TFA |
|
|
|
|
|
|
|
|
| CA-074 |
|
|
|
|
|
|
|
99.94% |
| CA-074 methyl ester |
|
|
|
|
|
|
|
99.81% |
| CAA-0225 |
|
|
|
|
|
|
|
|
| Calpeptin |
|
|
|
|
|
|
|
99.17% |
| CatD-IN-1 |
|
|
|
|
|
|
|
99.27% |
| Cathepsin C-IN-3 |
|
|
|
|
|
|
|
|
| Cathepsin C-IN-4 |
|
|
|
|
|
|
|
|
| Cathepsin C-IN-5 |
|
|
|
|
|
|
|
95.70% |
| Cathepsin C-IN-6 |
|
|
|
|
|
|
|
|
| Cathepsin C-IN-7 |
|
|
|
|
|
|
|
|
| Cathepsin D and E FRET Substrate |
|
|
|
|
|
|
|
|
| Cathepsin D and E FRET Substrate acetate |
|
|
|
|
|
|
|
99.75% |
| Cathepsin D degrader 1 |
|
|
|
|
|
|
|
|
| Cathepsin E substrate e |
|
|
|
|
|
|
|
|
| Cathepsin G |
|
|
|
|
|
|
|
|
| Cathepsin G Inhibitor I |
|
|
|
|
|
|
|
95.0% |
| Cathepsin inhibitor 1 |
|
|
|
|
|
|
|
99.28% |
| Cathepsin Inhibitor 2 |
|
|
|
|
|
|
|
99.77% |
| Cathepsin Inhibitor 4 |
|
|
|
|
|
|
|
|
| Cathepsin K inhibitor 2 |
|
|
|
|
|
|
|
|
| Cathepsin K inhibitor 3 |
|
|
|
|
|
|
|
|
| Cathepsin K inhibitor 4 |
|
|
|
|
|
|
|
|
| Cathepsin K inhibitor 5 |
|
|
|
|
|
|
|
|
| Cathepsin K inhibitor 6 |
|
|
|
|
|
|
|
98.18% |
| Cathepsin K inhibitor 7 |
|
|
|
|
|
|
|
|
| Cathepsin K-IN-8 |
|
|
|
|
|
|
|
|
| Cathepsin K-IN-9 |
|
|
|
|
|
|
|
|
| Cathepsin L-IN-2 |
|
|
|
|
|
|
|
98.02% |
| Cathepsin L-IN-3 |
|
|
|
|
|
|
|
|
| Cathepsin L-IN-3 TFA |
|
|
|
|
|
|
|
98.18% |
| Cathepsin L-IN-4 |
|
|
|
|
|
|
|
|
| Cathepsin L-IN-5 |
|
|
|
|
|
|
|
96.05% |
| Cathepsin L-IN-6 |
|
|
|
|
|
|
|
|
| Cathepsin L-IN-7 |
|
|
|
|
|
|
|
|
| Cathepsin L/S-IN-1 |
|
|
|
|
|
|
|
99.89% |
| Cathepsin S-IN-1 |
|
|
|
|
|
|
|
|
| Cathepsin X-IN-1 |
|
|
|
|
|
|
|
99.62% |
| Cathepsin-IN-5 |
|
|
|
|
|
|
|
|
| CLIK-148 |
|
|
|
|
|
|
|
|
| CTSB Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Ctsb Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Ctsb Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| CTSC Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Ctsc Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Ctsc Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| CTSC-IN-1 |
|
|
|
|
|
|
|
|
| CTSD Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Ctsd Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Ctsd Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| CTSE Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Ctse Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Ctse Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| CTSK Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Ctsk Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Ctsk Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| CTSL Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Ctsl Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Ctsl Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| CTSL/B-IN-1 |
|
|
|
|
|
|
|
|
| CTSL/CAPN1-IN-1 |
|
|
|
|
|
|
|
|
| CTSL/CAPN1-IN-2 |
|
|
|
|
|
|
|
|
| diABZI-V/C-Mal |
|
|
|
|
|
|
|
99.28% |
| Diazepinomicin |
|
|
|
|
|
|
|
|
| Dibenzyl trisulfide |
|
|
|
|
|
|
|
98.24% |
| Dual Cathepsin L/JAK-IN-1 |
|
|
|
|
|
|
|
98.47% |
| Dutacatib |
|
|
|
|
|
|
|
|
| E 64c |
|
|
|
|
|
|
|
99.32% |
| E-64 |
|
|
|
|
|
|
|
99.95% |
| FGA139 |
|
|
|
|
|
|
|
|
| FGA145 |
|
|
|
|
|
|
|
|
| FGA146 |
|
|
|
|
|
|
|
|
| FK-Luc-BH |
|
|
|
|
|
|
|
|
| Gallinamide A TFA |
|
|
|
|
|
|
|
99.85% |
| GB111-NH2 |
|
|
|
|
|
|
|
|
| GB111-NH2 hydrochloride |
|
|
|
|
|
|
|
98.41% |
| Gly-Phe-β-naphthylamide |
|
|
|
|
|
|
|
99.92% |
| GN-604 |
|
|
|
|
|
|
|
|
| GSK-2793660 |
|
|
|
|
|
|
|
99.91% |
| GSK-2793660 free base |
|
|
|
|
|
|
|
|
| Gü1303 |
|
|
|
|
|
|
|
|
| Gü2602 |
|
|
|
|
|
|
|
98.13% |
| H-Gly-Arg-NH2 |
|
|
|
|
|
|
|
|
| H-Pro-Thr-Glu-Phe-p-nitro-Phe-Arg-Leu-OH |
|
|
|
|
|
|
|
|
| Hepcidin-1 (mouse) |
|
|
|
|
|
|
|
|
| Hepcidin-1 (mouse) TFA |
|
|
|
|
|
|
|
98.86% |
| Heterophyllin A |
|
|
|
|
|
|
|
|
| JNJ 10329670 |
|
|
|
|
|
|
|
|
| JNJ-10311795 |
|
|
|
|
|
|
|
|
| JPM-OEt |
|
|
|
|
|
|
|
98.99% |
| K777 |
|
|
|
|
|
|
|
99.14% |
| K777 tosylate |
|
|
|
|
|
|
|
|
| Kgp-IN-1 |
|
|
|
|
|
|
|
|
| Kgp-IN-1 hydrochloride |
|
|
|
|
|
|
|
97.18% |
| KGP94 |
|
|
|
|
|
|
|
99.77% |
| KYS-1 |
|
|
|
|
|
|
|
99.34% |
| L-006235 |
|
|
|
|
|
|
|
99.74% |
| L-873724 |
|
|
|
|
|
|
|
98.93% |
| L-Homocysteine-d4 |
|
|
|
|
|
|
|
|
| L-Arginine-7-amido-4-methylcoumarin hydrochloride |
|
|
|
|
|
|
|
99.23% |
| Poly-L-Glutamic acid (MW 100000) |
|
|
|
|
|
|
|
|
| Poly-L-Glutamic acid (MW 700000) |
|
|
|
|
|
|
|
98.36% |
| L-Homocysteine |
|
|
|
|
|
|
|
98.0% |
| Lactacystin |
|
|
|
|
|
|
|
99.21% |
| LHVS |
|
|
|
|
|
|
|
98.15% |
| LmCPB-IN-1 |
|
|
|
|
|
|
|
|
| LN5P45 |
|
|
|
|
|
|
|
98.68% |
| LY 3000328 |
|
|
|
|
|
|
|
99.50% |
| MDL 27399 |
|
|
|
|
|
|
|
|
| MeOSuc-AAPV-CMK |
|
|
|
|
|
|
|
98.01% |
| MIV-247 |
|
|
|
|
|
|
|
|
| MK 1256 |
|
|
|
|
|
|
|
|
| MK-0674 |
|
|
|
|
|
|
|
|
| MPI8 |
|
|
|
|
|
|
|
|
| MPI8 TFA |
|
|
|
|
|
|
|
|
| Mpro/Cathepsin L-IN-1 |
|
|
|
|
|
|
|
|
| Mpro/Cathepsin L-IN-2 |
|
|
|
|
|
|
|
|
| MV061194 |
|
|
|
|
|
|
|
|
| N-CBZ-Phe-Arg-AMC |
|
|
|
|
|
|
|
99.40% |
| N-CBZ-Phe-Arg-AMC TFA |
|
|
|
|
|
|
|
99.79% |
| N-Ethylmaleimide |
|
|
|
|
|
|
|
99.59% |
| N-Ethylmaleimide-d5 |
|
|
|
|
|
|
|
99.84% |
| NB-216 |
|
|
|
|
|
|
|
|
| NB-533 |
|
|
|
|
|
|
|
|
| NC 2300 |
|
|
|
|
|
|
|
|
| NCO 700 sulfate |
|
|
|
|
|
|
|
|
| NCO-700 |
|
|
|
|
|
|
|
|
| NOTA-FZCD-3 |
|
|
|
|
|
|
|
|
| Olgotrelvir |
|
|
|
|
|
|
|
|
| Olgotrelvir sodium |
|
|
|
|
|
|
|
95.0% |
| ONO-5334 |
|
|
|
|
|
|
|
|
| ONO-5334 (Standard) |
|
|
|
|
|
|
|
|
| Oxocarbazate |
|
|
|
|
|
|
|
|
| Papain (lyophilized powder, ≥10 units/mg protein) |
|
|
|
|
|
|
|
|
| Papain inhibitor |
|
|
|
|
|
|
|
99.80% |
| PD 145305 |
|
|
|
|
|
|
|
95.0% |
| Petesicatib |
|
|
|
|
|
|
|
99.66% |
| Phe-Arg-Arg-Gly |
|
|
|
|
|
|
|
|
| PI3K-001 |
|
|
|
|
|
|
|
|
| Relacatib |
|
|
|
|
|
|
|
99.58% |
| RKLLW-NH2 |
|
|
|
|
|
|
|
|
| RO5461111 |
|
|
|
|
|
|
|
98.01% |
| S130 |
|
|
|
|
|
|
|
99.43% |
| S2160 |
|
|
|
|
|
|
|
|
| S2160 hydrochloride |
|
|
|
|
|
|
|
|
| SARS-CoV-2 3CLpro-IN-22 |
|
|
|
|
|
|
|
|
| SARS-CoV-2 3CLpro-IN-34 |
|
|
|
|
|
|
|
|
| SARS-CoV-2 3CLpro-IN-38 |
|
|
|
|
|
|
|
|
| SARS-CoV-2-IN-77 |
|
|
|
|
|
|
|
|
| SH491 |
|
|
|
|
|
|
|
|
| SID 26681509 |
|
|
|
|
|
|
|
99.16% |
| SID 26681509 quarterhydrate |
|
|
|
|
|
|
|
98.02% |
| SmCB1-IN-1 |
|
|
|
|
|
|
|
|
| SPR38 |
|
|
|
|
|
|
|
|
| SQ 32056 |
|
|
|
|
|
|
|
|
| SQ 32602 |
|
|
|
|
|
|
|
|
| SSAA09E1 |
|
|
|
|
|
|
|
99.54% |
| Suc-Val-Pro-Phe-pNA |
|
|
|
|
|
|
|
|
| Suc-Val-Pro-Phe-SBzl |
|
|
|
|
|
|
|
|
| Tasiamide B |
|
|
|
|
|
|
|
|
| TB-11 |
|
|
|
|
|
|
|
98.71% |
| TB-9 |
|
|
|
|
|
|
|
|
| TS-24 |
|
|
|
|
|
|
|
98.96% |
| TSC25 |
|
|
|
|
|
|
|
|
| UAWJ9-36-3 |
|
|
|
|
|
|
|
|
| VBY-825 |
|
|
|
|
|
|
|
99.81% |
| Verducatib |
|
|
|
|
|
|
|
98.94% |
| VK13 |
|
|
|
|
|
|
|
|
| Y1693 |
|
|
|
|
|
|
|
99.91% |
| Z-Arg-Arg-4MβNA triacetate |
|
|
|
|
|
|
|
|
| Z-Arg-Arg-AMC |
|
|
|
|
|
|
|
|
| Z-Arg-Arg-AMC hydrochloride |
|
|
|
|
|
|
|
99.87% |
| Z-Arg-Arg-pNA |
|
|
|
|
|
|
|
99.17% |
| Z-Arg-Arg-βNA acetate |
|
|
|
|
|
|
|
99.77% |
| Z-Arg-Lys-AOMK |
|
|
|
|
|
|
|
|
| Z-DEVD-CMK |
|
|
|
|
|
|
|
98.99% |
| Z-FA-FMK |
|
|
|
|
|
|
|
99.14% |
| Z-FF-FMK |
|
|
|
|
|
|
|
95.98% |
| Z-FG-NHO-Bz |
|
|
|
|
|
|
|
|
| Z-FG-NHO-BzOME |
|
|
|
|
|
|
|
98.02% |
| Z-FK-ck |
|
|
|
|
|
|
|
|
| Z-FY-CHO |
|
|
|
|
|
|
|
95.0% |
| Z-Gly-Pro-Arg-AMC hydrochloride |
|
|
|
|
|
|
|
99.15% |
| Z-L(D-Val)G-CHN2 |
|
|
|
|
|
|
|
99.35% |
| Z-Leu-Arg-AMC |
|
|
|
|
|
|
|
99.24% |
| Z-Leu-Leu-Arg-AMC |
|
|
|
|
|
|
|
99.27% |
| Z-Leu-Leu-Leu-fluoromethyl ketone |
|
|
|
|
|
|
|
|
| Z-Leu-Tyr-Chloromethylketone |
|
|
|
|
|
|
|
|
| Z-LVG |
|
|
|
|
|
|
|
|
| Z-LVG-CHN2 |
|
|
|
|
|
|
|
99.88% |
| Z-LVG-CHN2 (Standard) |
|
|
|
|
|
|
|
|
| Z-Nle-Lys-Arg-AMC |
|
|
|
|
|
|
|
|
| Z-Nle-Lys-Arg-AMC acetate |
|
|
|
|
|
|
|
99.58% |
| Z-Phe-Ala-diazomethylketone |
|
|
|
|
|
|
|
98.06% |
| N-CBZ-Phe-Arg-AMC hydrochloride |
|
|
|
|
|
|
|
99.40% |
| Z-Phe-Arg-pNA |
|
|
|
|
|
|
|
99.87% |
| Z-Phe-Phe-Diazomethylketone |
|
|
|
|
|
|
|
90.11% |
| Z-Phe-Tyr(tBu)-diazomethylketone |
|
|
|
|
|
|
|
98.04% |
| Z-Val-Val-Arg-AMC |
|
|
|
|
|
|
|
99.44% |
| Z-Val-Val-Nle-diazomethylketone |
|
|
|
|
|
|
|
|
| Z-WEHD-FMK |
|
|
|
|
|
|
|
98.0% |
| Leupeptin |
|
|
|
|
|
|
|
|
| Leupeptin hemisulfate |
|
|
|
|
|
|
|
99.39% |
| human Cystatin-C protein |
|
|
|
|
|
|
|
98% |
| Cysteine Protease inhibitor |
|
|
|
|
|
|
|
95.23% |
| Cysteine Protease inhibitor hydrochloride |
|
|
|
|
|
|
|
96.01% |
| Odanacatib |
|
|
|
|
|
|
|
99.78% |
| p-Aminophenylmercuric acetate |
|
|
|
|
|
|
|
98.32% |
| Balicatib |
|
|
|
|
|
|
|
98.25% |
| Papain |
|
|
|
|
|
|
|
|
| Papain (1.5-10 units/mg) |
|
|
|
|
|
|
|
|
| papain (USP) |
|
|
|
|
|
|
|
|
| Gardenin B |
|
|
|
|
|
|
|
99.69% |
| Cathepsin B, Human Liver |
|
|
|
|
|
|
|
|
| Cathepsin C |
|
|
|
|
|
|
|
|
| Cathepsin K |
|
|
|
|
|
|
|
|
| Cathepsin L |
|
|
|
|
|
|
|
|
| Poly-L-glutamic acid sodium salt (MW 120000) |
|
|
|
|
|
|
|
|
| Poly-L-glutamic acid sodium salt (MW 15000) |
|
|
|
|
|
|
|
|
| Poly-L-glutamic acid sodium salt (MW 3000) |
|
|
|
|
|
|
|
|
| Poly-L-glutamic acid sodium salt (MW 30000) |
|
|
|
|
|
|
|
|
| Poly-L-glutamic acid sodium salt (MW 45000) |
|
|
|
|
|
|
|
|
| Poly-L-glutamic acid sodium salt (MW 60000) |
|
|
|
|
|
|
|
|
| Poly-L-glutamic acid sodium salt (MW 7500) |
|
|
|
|
|
|
|
|
| PMSF |
|
|
|
|
|
|
|
99.83% |
| Estatin B |
|
|
|
|
|
|
|
|
| Calpain-1 (pig) |
|
|
|
|
|
|
|
|
| Aloxistatin |
|
|
|
|
|
|
|
99.94% |